Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dexmedetomidine Nasal Spray for Palliative Sedation in Terminal Cancer Patients
ChiCTR2500110418Phase 4Not yet recruiting
- Sponsor
- Zhejiang Hospital
- Start
- Oct 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of dexmedetomidine in cancer (3 arms), sponsored by Zhejiang Hospital. Primary endpoints: Duration of sedation and Success rate of sedation. Planned start Oct 2025; status: not yet recruiting.
02
Drugs
dexmedetomidine
03
Conditions
cancer
Beyond the preview
Go deeper on ChiCTR2500110418.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500110418.